Epigenetics Core
Epigenetics Core
批准号:
7540231
负责人:
MICHAEL A TEITELL
金额:
$10.78万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-08-01 至 2013-07-31
关键词:
AcademiaAdoptedAdoptionAreaBioinformaticsBiological AssayCell CountCellsChromatinCommunitiesConditionCore FacilityCytogeneticsDNADNA MethylationDataData CollectionDetectionEpigenetic ProcessGene ExpressionGene TargetingGenesGenomeGenomicsGrowthHistone H3HistonesHuman ResourcesHybridization ArrayJonsson Comprehensive Cancer Center of University of California Los AngelesLettersLinkMeasurementMethodsMethylationModificationMolecular ProfilingPan GenusPatternPolymerase Chain ReactionProceduresProcessProtocols documentationPublishingRoleSamplingScienceServicesStandards of Weights and MeasuresTechniquesTechnologyTrainingTranscription Initiation SiteUC01UC06ValidationWA01 cell lineWA09 Cell Lineadvanced systemanalytical toolbisulfitechromatin immunoprecipitationcomparativedata acquisitiongenome sequencinghuman embryonic stem cellinterestprogramspromotertechnology developmenttool development
中文摘要
表观遗传学核心(核心C)提供全基因组的DNA甲基化、组蛋白修饰和染色质
免疫沉淀(CHIP)服务,以及目标基因区域分析和验证,以支持
计划项目。表观遗传学核心提供到管理核心A的服务的直接链接,
HESC核心B、计算/生物信息学核心D以及必要的现有UCLA核心,包括
基因表达核心设施(S·尼尔森)。表观遗传学核心得到了安捷伦的大力支持
技术(用于阵列平台、探头技术以及分析工具的开发和采用)以及
支持核心服务的关键顾问,包括C Plass和T Huang(DMA甲基化),M Grunstein
和S·库尔迪斯塔尼(组蛋白修饰)和H·雪松(CHIP)。核心C将提供全基因组或有针对性的
人类胚胎干细胞及其衍生分化细胞DNA甲基化改变模式的检测和验证
来自hESC核心B和计划项目1-3。核心C提供芯片程序、探头
制造、阵列杂交、数据收集和通过将数据传输到计算/
生物信息学核心D.表观遗传学核心将分发信息和协议,并帮助培训
每个计划项目和核心中的人员(根据需要),并将发挥有限但重要的作用
在技术开发方面,主要致力于减少阵列Chlp芯片技术的单元数输入
与核心用户合作,并评估/纳入表观遗传修饰检测方面的进展
可通过一般科学界以及与安捷伦技术公司联合使用。进入
用于高级ChlP芯片分析的Solexa 1G高通量测序系统是通过UCLA
基因表达核心设施(S·尼尔森)。作为对计划项目和
对于整个hESC社区,表观遗传学核心C将提供全球DNA的基线测量
甲基化,泛乙酰化组蛋白H3和H4,以及二甲基化和三甲基化的组蛋白,表观遗传标记
反映活跃或沉默的基因表达,用于联邦批准的最佳低传代hESC系
UC 01(HSF-1)、UC 06(HSF-6)、WA01(H1)和Wa09(H9)进行比较分析。表达特征分析
对于这4个联邦批准的品系(已经发表或将在现有的UCLA基因中执行
表达核心设备)将在表观遗传特征和对hESC基因的影响之间提供联系
表情。此信息将在计划项目的公开可访问部分中提供
网站,有数据输入和操作密码保护。
英文摘要
The Epigenetics Core (Core C) provides genome-wide DMA methylation, histone modification, and chromatin
immunoprecipitation (ChIP) services, along with targeted gene region analysis and validation, to support the
Program Projects. The Epigenetics Core provides direct linkage of services to the Administrative Core A,
hESC Core B, Computational/Bioinformatics Core D and also to essential existing UCLA cores, including the
Gene Expression Core Facility (S Nelson). The Epigenetics Core is strongly supported by Agilent
Technologies (for array platforms, probe technologies, and analytical tool development and adoption) and by
key consultants that support Core services, including C Plass and T Huang (DMA methylation), M Grunstein
and S Kurdistani (histone modification), and H Cedar (ChIP). Core C will provide genome-wide or targeted
detection and validation for altered patterns of DNA methylation in hESCs and derivative differentiated cells
from the hESC Core B and from Program Projects 1-3. Core C provides ChIP procedures, probe
manufacture, array hybridizations, data collection, and analysis through transfer of data to Computational/
Bioinformatics Core D. The Epigenetics Core will distribute information and protocols and help train
personnel (as needed) in each of the Program Projects and Cores and will have a limited but important role
in technology development, focusing mainly on reducing cell number inputs for array ChlP-chip technologies
with Core users and assessing/incorporating advances in epigenetic modification detection as they become
available through the general scientific community and in conjunction with Agilent Technologies. Access to
the Solexa 1G high throughput sequencing system for advanced ChlP-chip analysis is through the UCLA
Gene Expression Core Facility (S Nelson). As an essential comparative service to the Program Project and
to the hESC community as a whole, Epigenetics Core C will provide baseline measurements of global DNA
methylation, pan-acetylated histone H3 and H4, and di- and tri-methylated histones, epigenetic markings that
reflect active or silenced gene expression, for optimally grown low-passage federally-approved hESC lines
UC 01 (HSF-1), UC 06 (HSF-6), WA01 (H1), and Wa09 (H9) for comparative analysis. Expression profiling
for these 4 federally-approved lines (already published or to be performed in the existing UCLA Gene
Expression Core Facility) will provide a link between epigenetic signatures and effects on hESC gene
expression. This information will be made available in a publicly accessible portion of the Program Project
Website, with data entry and manipulation password protected.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Epigenetics Core
-
批准号:8379989
-
项目类别:
-
资助金额:$18.11万
-
财政年份:2012
-
负责人:MICHAEL A TEITELL
-
依托单位:
A Fourth Outcome: DNA Damage and the Differentiation of B Cells
-
批准号:8447385
-
项目类别:
-
资助金额:$29.6万
-
财政年份:2011
-
负责人:MICHAEL A TEITELL
-
依托单位:
A Fourth Outcome: DNA Damage and the Differentiation of B Cells
-
批准号:8050719
-
项目类别:
-
资助金额:$31.49万
-
财政年份:2011
-
负责人:MICHAEL A TEITELL
-
依托单位:
A Fourth Outcome: DNA Damage and the Differentiation of B Cells
-
批准号:8633428
-
项目类别:
-
资助金额:$30.54万
-
财政年份:2011
-
负责人:MICHAEL A TEITELL
-
依托单位:
A NOVEL MECHANISM OF TCL1 TUMORIGENESIS
-
批准号:6880146
-
项目类别:
-
资助金额:$28.46万
-
财政年份:2004
-
负责人:MICHAEL A TEITELL
-
依托单位:
A NOVEL MECHANISM OF TCL1 TUMORIGENESIS
-
批准号:7213270
-
项目类别:
-
资助金额:$27.03万
-
财政年份:2004
-
负责人:MICHAEL A TEITELL
-
依托单位:
A NOVEL MECHANISM OF TCL1 TUMORIGENESIS
-
批准号:6768423
-
项目类别:
-
资助金额:$28.27万
-
财政年份:2004
-
负责人:MICHAEL A TEITELL
-
依托单位:
A NOVEL MECHANISM OF TCL1 TUMORIGENESIS
-
批准号:7022309
-
项目类别:
-
资助金额:$27.84万
-
财政年份:2004
-
负责人:MICHAEL A TEITELL
-
依托单位:
A NOVEL MECHANISM OF TCL1 TUMORIGENESIS
-
批准号:7367797
-
项目类别:
-
资助金额:$27.03万
-
财政年份:2004
-
负责人:MICHAEL A TEITELL
-
依托单位:
TCL1 ONCOGENE IN B LYMPHOCYTE DEVELOPMENT AND NEOPLASIA
-
批准号:6507940
-
项目类别:
-
资助金额:$26.78万
-
财政年份:2002
-
负责人:MICHAEL A TEITELL
-
依托单位:
TCL1 ONCOGENE IN B LYMPHOCYTE DEVELOPMENT AND NEOPLASIA
-
批准号:7050967
-
项目类别:
-
资助金额:$0.88万
-
财政年份:2002
-
负责人:MICHAEL A TEITELL
-
依托单位:
CRTC2 in Cellular Development, Function, and Neoplasia
-
批准号:8130653
-
项目类别:
-
资助金额:$27.3万
-
财政年份:2002
-
负责人:MICHAEL A TEITELL
-
依托单位:
CRTC2 in Cellular Development, Function, and Neoplasia
-
批准号:8462450
-
项目类别:
-
资助金额:$25.66万
-
财政年份:2002
-
负责人:MICHAEL A TEITELL
-
依托单位:
TCL1 ONCOGENE IN B LYMPHOCYTE DEVELOPMENT AND NEOPLASIA
-
批准号:6772509
-
项目类别:
-
资助金额:$29.09万
-
财政年份:2002
-
负责人:MICHAEL A TEITELL
-
依托单位:
TCL1 ONCOGENE IN B LYMPHOCYTE DEVELOPMENT AND NEOPLASIA
-
批准号:6914836
-
项目类别:
-
资助金额:$26.78万
-
财政年份:2002
-
负责人:MICHAEL A TEITELL
-
依托单位:
TCL1 ONCOGENE IN B LYMPHOCYTE DEVELOPMENT AND NEOPLASIA
-
批准号:7075410
-
项目类别:
-
资助金额:$26.16万
-
财政年份:2002
-
负责人:MICHAEL A TEITELL
-
依托单位:
TCL1 ONCOGENE IN B LYMPHOCYTE DEVELOPMENT AND NEOPLASIA
-
批准号:6641279
-
项目类别:
-
资助金额:$26.78万
-
财政年份:2002
-
负责人:MICHAEL A TEITELL
-
依托单位:
CRTC2 in Cellular Development, Function, and Neoplasia
-
批准号:8677727
-
项目类别:
-
资助金额:$26.48万
-
财政年份:2002
-
负责人:MICHAEL A TEITELL
-
依托单位:
TCL1 Oncogene in B Lymphocyte Development and Neoplasia
-
批准号:7486806
-
项目类别:
-
资助金额:$26.62万
-
财政年份:2002
-
负责人:MICHAEL A TEITELL
-
依托单位:
TCL1 Oncogene in B Lymphocyte Development and Neoplasia
-
批准号:7901615
-
项目类别:
-
资助金额:$26.62万
-
财政年份:2002
-
负责人:MICHAEL A TEITELL
-
依托单位:
海外基金